First comprehensive guideline on using biomarkers for monitoring Crohn's disease, making medicine with AI

Sign Up / About

First comprehensive guideline on using biomarkers for monitoring Crohn's disease (2 minute read)

The American Gastroenterological Association (AGA) recommends blood and stool-based biomarkers, such as C-reactive protein and fecal calprotectin, to manage Crohn's disease, an inflammatory bowel disease affecting 2.74 million in the U.S. The guideline suggests regular biomarker checks for disease activity assessment, emphasizing their utility alongside colonoscopies. For patients in remission, tests every 6-12 months are advised, and for those with active symptoms, checks every 2-4 months are recommended before treatment adjustments. The guideline deems biomarkers integral to Crohn's disease care, offering a less invasive and cost-effective alternative to frequent colonoscopies for improved long-term outcomes.

Making medicine with Artificial Intelligence (3 minute read)

The Hunter Medical Research Institute (HMRI) is utilizing Artificial Intelligence (AI) to advance research on Inflammatory Bowel Disease (IBD) and Ulcerative Colitis. A $98,700 grant from Newcastle Permanent Charitable Foundation supports this cutting-edge exploration. Dr. Gerard Kaiko and his team are employing AI, specifically neural networks, to analyze vast datasets related to the gut microbiome. The goal is to identify new therapies beyond immune suppression for IBD, focusing on intestinal stem cells and microbiome balance. The project, funded by Newcastle Permanent, aims to develop innovative treatments and has already defined a potential "microbiome therapy." The research not only addresses IBD but also holds promise for other diseases. With approximately 100,000 Australians affected by IBD, the initiative reflects the importance of technological advancements in healthcare, supported by local partnerships. The funding is crucial for progressing studies and has enabled collaboration with industry partners in Melbourne and Japan, moving towards clinical trials. The Newcastle Permanent Charitable Foundation applauds the groundbreaking research, emphasizing the need for increased attention to gut diseases affecting 1 in 5 Australians. The HMRI, a partnership between the University of Newcastle, Hunter New England Health, and the community, underscores the potential impact of AI-driven biotechnological solutions on future healthcare.

What is ulcerative colitis? An expert explains what causes the inflammatory bowel disease and how to manage it (2 minute read)

Ulcerative colitis, a common inflammatory bowel disease, primarily affects the colon's inner lining. Dr. George Nikias explains it shares similarities with Crohn's disease but is limited to the large intestine. While its exact cause is unclear, a genetic predisposition coupled with environmental factors, such as diet, may contribute. Treatment involves medication to control inflammation, symptoms, and complications. Nikias emphasizes the importance of consulting a healthcare professional if experiencing symptoms like abdominal cramping or bleeding. Early evaluation is crucial for managing the condition effectively.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape (4 minute read)

In the last two months, the ulcerative colitis (UC) treatment landscape has expanded with the approval of four new options, including Lilly's Omvoh and Pfizer's Velsipity. Insights from Spherix Global Insights' Q3 update show heightened anticipation for the Entyvio line-extension. Gastroenterologists express significant enthusiasm for Entyvio subcutaneous (SC), but its overall market impact is projected to be modest. Lilly’s Omvoh, a first-in-class IL-23 inhibitor, may have broader market implications, with specialists anticipating success in patients resistant to Janssen’s Stelara. Velsipity, an oral agent, is expected to disrupt the market, aligning with Zeposia in market share projections. The emergence of oral agents may delay the adoption of traditional biologics. Spherix will track the first 18 months of Entyvio SC, Velsipity, and Omvoh through its Launch Dynamix™ series, providing updates on key performance indicators. The RealTime Dynamix™ service will monitor the overall market impact of these entrants. Spherix Global Insights specializes in market research for various therapeutic areas.

How Long Does It Take for Prednisone to Work in IBD? (5 minute read)

Prednisone, a corticosteroid, quickly relieves symptoms of Crohn's disease or ulcerative colitis by suppressing the immune system and reducing inflammation. It typically works within days, easing pain, diarrhea, and bleeding. While effective for short-term use, its long-term use can lead to side effects like mood swings and weight gain. Prednisone interacts with certain medications, and caution is advised with alcohol and specific foods. Timing and gradual tapering off are crucial. It may not be suitable for those with certain health conditions. Overall, prednisone is a potent, fast-acting medication for inflammatory bowel diseases with manageable side effects when used judiciously.

A woman did more than 100 stool transplants to treat her ulcerative colitis — and it worked. What to know about fecal microbiota transplantation (6 minute read)

Saffron Cassaday, diagnosed with ulcerative colitis, struggled with debilitating symptoms and ineffective medications. Unable to access fecal microbiota transplantation (FMT) due to FDA restrictions, she undertook a DIY approach using her partner's stool. After over 100 self-administered transfers, Cassaday, now symptom-free for three years, explores her journey in the film "Designer S***." FMT, also known as intestinal microbiota transplant (IMT), involves transferring a screened donor's healthy microbiota to restore intestinal health. While effective for C. diff infections, its success in treating ulcerative colitis is lower. Dr. Ari Grinspan urges caution, emphasizing the risks and the need for clinical trials to assess FMT's potential in various conditions.